Jonathan McNeill, See Remarks at Dyne Therapeutics, Inc. (DYN), sold 481 shares at $8.73 ($4K) on 2022-03-11, disclosed to the SEC on 2022-03-14.
Scheduled sale ($4k) by See Remarks under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| DYN | SELL | 2024-08-20 | $122K | — | Filing → |
| DYN | SELL | 2024-06-11 | $114K | — | Filing → |
| DYN | SELL | 2024-05-17 | $143K | — | Filing → |